English

Lexicon Pharmaceuticals, Inc.

EDGAR

LXRX Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 49.8M, using the latest reported figures. The previous period, 2024, was about USD 31.08M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

692 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 692000 USD Source

Operating margin

-3,835.26%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -26540000 USD Source
Revenue: 692000 USD Source

Operating cash flow

-9.19 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -23922000 USD Source
Operating Cash Flow: -14730000 USD Source

Cash and cash equivalents: 40.9 million USD 2026-06-30 Source
Exact value

40924000 USD
Long-term debt including current maturities: 99.3 million USD 2023-09-30 Source
Exact value

99300000 USD
Shares outstanding: 447 million shares 2026-06-30 Source
Exact value

446870629 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

41.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 14182000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 49803000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 44310000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 21102000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 692000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-61.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -12769000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -50341000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -34811000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -1043000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -31775000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-65 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -50618000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -26785000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -67851000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -50618000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -14730000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -23922000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -14730000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2022-12-31
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+60.2%

Prior period

USD 31.08 million

2024-01-01 – 2024-12-31
Current period

USD 49.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

49803000 − 31081000 = 18722000 USD

31081000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
49803000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Year-over-year change in Revenue: 18722000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 49803000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#779636 Filing: 000106282226000050 Input fundies:Revenue: 31081000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#780255 Filing: 000106282226000050
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 150.06 million

Prior period

−USD 200.4 million

2024-01-01 – 2024-12-31
Current period

−USD 50.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-50341000 − -200403000 = 150062000 USD

-200403000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-50341000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Year-over-year change in Net income: 150062000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -50341000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#984693 Filing: 000106282226000050 Input fundies:NetIncome: -200403000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#985466 Filing: 000106282226000050
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 110.93 million

Prior period

−USD 178.78 million

2024-01-01 – 2024-12-31
Current period

−USD 67.85 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-67851000 − -178780000 = 110929000 USD

-178780000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-67851000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Year-over-year change in Operating cash flow: 110929000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -67851000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1010429 Filing: 000106282226000050 Input fundies:OperatingCashFlow: -178780000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1011084 Filing: 000106282226000050
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 1.03 million

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 1031000 = -1031000 USD

1031000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Year-over-year change in Capital expenditure: -1031000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1013515 Filing: 000106282226000050 Input fundies:CapitalExpenditure: 1031000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1014107 Filing: 000106282226000050
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 49.8 million 100% of revenue
Cost of revenue USD 274,000 0.6% of revenue
Operating expenses USD 98.44 million 198% of revenue
Operating income −USD 48.91 million −98% of revenue
Tax, interest and other Derived USD 1.43 million 2.9% of revenue
Net income −USD 50.34 million −101% of revenue

Cash

Operating cash flow −USD 67.85 million −136% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 67.85 million −136% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 260% of revenue.
2017 Operating loss: operating costs were 242% of revenue.
2018 Operating loss: operating costs were 263% of revenue.
2019 40%56%
2020 Operating loss: operating costs were 299% of revenue.
2021 Operating loss: operating costs were 29,325% of revenue.
2022 Operating loss: operating costs were 72,589% of revenue.
2023 Operating loss: operating costs were 14,365% of revenue.
2024 Operating loss: operating costs were 734% of revenue.
2025 Operating loss: operating costs were 198% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	79256000	206427000 Derived	-127171000	4274000 Derived	-131445000	-175859000 Derived	Source 2016-01-01 – 2016-12-31: 79256000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -127171000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -131445000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -175628000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 231000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	91689000	222313000 Derived	-130624000	-7631000 Derived	-122993000	-185622000 Derived	Source 2017-01-01 – 2017-12-31: 91689000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -130624000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -122993000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -185394000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 228000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	63209000	166488000 Derived	-103279000	17269000 Derived	-120548000	-148702000 Derived	Source 2018-01-01 – 2018-12-31: 63209000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -103279000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -120548000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -148607000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 95000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	322073000	180628000 Derived	141445000	11312000 Derived	130133000	113737000 Derived	Source 2019-01-01 – 2019-12-31: 322073000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 141445000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 130133000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 113807000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 70000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	23995000	71795000 Derived	-47800000	10774000 Derived	-58574000	-143056000 Derived	Source 2020-01-01 – 2020-12-31: 23995000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -47800000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -58574000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -142969000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 87000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	298000	87388000 Derived	-87090000	668000 Derived	-87758000	-88238000 Derived	Source 2021-01-01 – 2021-12-31: 298000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -87090000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -87758000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -87017000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1221000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	139000	100899000 Derived	-100760000	1184000 Derived	-101944000	-90177000 Derived	Source 2022-01-01 – 2022-12-31: 139000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -100760000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -101944000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -88851000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1326000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1204000	172954000 Derived	-171750000	5369000 Derived	-177119000	-162367000 Derived	Source 2023-01-01 – 2023-12-31: 1204000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -171750000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -177119000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -161897000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 470000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	31081000	228198000 Derived	-197117000	3286000 Derived	-200403000	-179811000 Derived	Source 2024-01-01 – 2024-12-31: 31081000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -197117000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -200403000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -178780000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1031000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	49803000	98714000 Derived	-48911000	1430000 Derived	-50341000	-67851000 Derived	Source 2025-01-01 – 2025-12-31: 49803000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -48911000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -50341000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -67851000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 49.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	79256000	Revenue: 79256000 Open source
20172017-12-31	Revenue	91689000	Revenue: 91689000 Open source
20182018-12-31	Revenue	63209000	Revenue: 63209000 Open source
20192019-12-31	Revenue	322073000	Revenue: 322073000 Open source
20202020-12-31	Revenue	23995000	Revenue: 23995000 Open source
20212021-12-31	Revenue	298000	Revenue: 298000 Open source
20222022-12-31	Revenue	139000	Revenue: 139000 Open source
20232023-12-31	Revenue	1204000	Revenue: 1204000 Open source
20242024-12-31	Revenue	31081000	Revenue: 31081000 Open source
20252025-12-31	Revenue	49803000	Revenue: 49803000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

60.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-39%	Revenue: 79256000 Open source Revenue: 130014000 Open source
20172017-12-31	Year over year	15.7%	Revenue: 91689000 Open source Revenue: 79256000 Open source
20182018-12-31	Year over year	-31.1%	Revenue: 63209000 Open source Revenue: 91689000 Open source
20192019-12-31	Year over year	409.5%	Revenue: 322073000 Open source Revenue: 63209000 Open source
20202020-12-31	Year over year	-92.5%	Revenue: 23995000 Open source Revenue: 322073000 Open source
20212021-12-31	Year over year	-98.8%	Revenue: 298000 Open source Revenue: 23995000 Open source
20222022-12-31	Year over year	-53.4%	Revenue: 139000 Open source Revenue: 298000 Open source
20232023-12-31	Year over year	766.2%	Revenue: 1204000 Open source Revenue: 139000 Open source
20242024-12-31	Year over year	2,481.5%	Revenue: 31081000 Open source Revenue: 1204000 Open source
20252025-12-31	Year over year	60.2%	Revenue: 49803000 Open source Revenue: 31081000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -98.2% 2025

Net margin -101.1% 2025

Free cash flow margin -136.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-160.5%	Operating Income: -127171000 Open source Revenue: 79256000 Open source
20172017-12-31	Operating margin	-142.5%	Operating Income: -130624000 Open source Revenue: 91689000 Open source
20182018-12-31	Operating margin	-163.4%	Operating Income: -103279000 Open source Revenue: 63209000 Open source
20192019-12-31	Operating margin	43.9%	Operating Income: 141445000 Open source Revenue: 322073000 Open source
20202020-12-31	Operating margin	-199.2%	Operating Income: -47800000 Open source Revenue: 23995000 Open source
20212021-12-31	Operating margin	-29,224.8%	Operating Income: -87090000 Open source Revenue: 298000 Open source
20222022-12-31	Operating margin	-72,489.2%	Operating Income: -100760000 Open source Revenue: 139000 Open source
20232023-12-31	Operating margin	-14,265%	Operating Income: -171750000 Open source Revenue: 1204000 Open source
20242024-12-31	Operating margin	-634.2%	Operating Income: -197117000 Open source Revenue: 31081000 Open source
20252025-12-31	Operating margin	-98.2%	Operating Income: -48911000 Open source Revenue: 49803000 Open source
20162016-12-31	Net margin	-165.8%	Net Income: -131445000 Open source Revenue: 79256000 Open source
20172017-12-31	Net margin	-134.1%	Net Income: -122993000 Open source Revenue: 91689000 Open source
20182018-12-31	Net margin	-190.7%	Net Income: -120548000 Open source Revenue: 63209000 Open source
20192019-12-31	Net margin	40.4%	Net Income: 130133000 Open source Revenue: 322073000 Open source
20202020-12-31	Net margin	-244.1%	Net Income: -58574000 Open source Revenue: 23995000 Open source
20212021-12-31	Net margin	-29,449%	Net Income: -87758000 Open source Revenue: 298000 Open source
20222022-12-31	Net margin	-73,341%	Net Income: -101944000 Open source Revenue: 139000 Open source
20232023-12-31	Net margin	-14,710.9%	Net Income: -177119000 Open source Revenue: 1204000 Open source
20242024-12-31	Net margin	-644.8%	Net Income: -200403000 Open source Revenue: 31081000 Open source
20252025-12-31	Net margin	-101.1%	Net Income: -50341000 Open source Revenue: 49803000 Open source
20162016-12-31	Free cash flow margin	-221.9%	Revenue: 79256000 Open source Operating Cash Flow: -175628000 Open source Capital Expenditure: 231000 Open source
20172017-12-31	Free cash flow margin	-202.4%	Revenue: 91689000 Open source Operating Cash Flow: -185394000 Open source Capital Expenditure: 228000 Open source
20182018-12-31	Free cash flow margin	-235.3%	Revenue: 63209000 Open source Operating Cash Flow: -148607000 Open source Capital Expenditure: 95000 Open source
20192019-12-31	Free cash flow margin	35.3%	Revenue: 322073000 Open source Operating Cash Flow: 113807000 Open source Capital Expenditure: 70000 Open source
20202020-12-31	Free cash flow margin	-596.2%	Revenue: 23995000 Open source Operating Cash Flow: -142969000 Open source Capital Expenditure: 87000 Open source
20212021-12-31	Free cash flow margin	-29,610.1%	Revenue: 298000 Open source Operating Cash Flow: -87017000 Open source Capital Expenditure: 1221000 Open source
20222022-12-31	Free cash flow margin	-64,875.5%	Revenue: 139000 Open source Operating Cash Flow: -88851000 Open source Capital Expenditure: 1326000 Open source
20232023-12-31	Free cash flow margin	-13,485.6%	Revenue: 1204000 Open source Operating Cash Flow: -161897000 Open source Capital Expenditure: 470000 Open source
20242024-12-31	Free cash flow margin	-578.5%	Revenue: 31081000 Open source Operating Cash Flow: -178780000 Open source Capital Expenditure: 1031000 Open source
20252025-12-31	Free cash flow margin	-136.2%	Revenue: 49803000 Open source Operating Cash Flow: -67851000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -67.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-175628000	Operating Cash Flow: -175628000 Open source
20172017-12-31	Operating cash flow	-185394000	Operating Cash Flow: -185394000 Open source
20182018-12-31	Operating cash flow	-148607000	Operating Cash Flow: -148607000 Open source
20192019-12-31	Operating cash flow	113807000	Operating Cash Flow: 113807000 Open source
20202020-12-31	Operating cash flow	-142969000	Operating Cash Flow: -142969000 Open source
20212021-12-31	Operating cash flow	-87017000	Operating Cash Flow: -87017000 Open source
20222022-12-31	Operating cash flow	-88851000	Operating Cash Flow: -88851000 Open source
20232023-12-31	Operating cash flow	-161897000	Operating Cash Flow: -161897000 Open source
20242024-12-31	Operating cash flow	-178780000	Operating Cash Flow: -178780000 Open source
20252025-12-31	Operating cash flow	-67851000	Operating Cash Flow: -67851000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -67.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-175859000	Operating Cash Flow: -175628000 Open source Capital Expenditure: 231000 Open source
20172017-12-31	Free cash flow	-185622000	Operating Cash Flow: -185394000 Open source Capital Expenditure: 228000 Open source
20182018-12-31	Free cash flow	-148702000	Operating Cash Flow: -148607000 Open source Capital Expenditure: 95000 Open source
20192019-12-31	Free cash flow	113737000	Operating Cash Flow: 113807000 Open source Capital Expenditure: 70000 Open source
20202020-12-31	Free cash flow	-143056000	Operating Cash Flow: -142969000 Open source Capital Expenditure: 87000 Open source
20212021-12-31	Free cash flow	-88238000	Operating Cash Flow: -87017000 Open source Capital Expenditure: 1221000 Open source
20222022-12-31	Free cash flow	-90177000	Operating Cash Flow: -88851000 Open source Capital Expenditure: 1326000 Open source
20232023-12-31	Free cash flow	-162367000	Operating Cash Flow: -161897000 Open source Capital Expenditure: 470000 Open source
20242024-12-31	Free cash flow	-179811000	Operating Cash Flow: -178780000 Open source Capital Expenditure: 1031000 Open source
20252025-12-31	Free cash flow	-67851000	Operating Cash Flow: -67851000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

41.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	66.9%	Total Liabilities: 318224000 Open source Total Assets: 475625000 Open source
20172017-12-31	Liabilities / assets	84.4%	Total Liabilities: 368274000 Open source Total Assets: 436539000 Open source
20182018-12-31	Liabilities / assets	109.3%	Total Liabilities: 310541000 Open source Total Assets: 284136000 Open source
20192019-12-31	Liabilities / assets	72%	Total Liabilities: 300614000 Open source Total Assets: 417715000 Open source
20202020-12-31	Liabilities / assets	23.3%	Total Liabilities: 47417000 Open source Total Assets: 203788000 Open source
20212021-12-31	Liabilities / assets	17%	Total Liabilities: 23314000 Open source Total Assets: 136909000 Open source
20222022-12-31	Liabilities / assets	39.7%	Total Liabilities: 77175000 Open source Total Assets: 194299000 Open source
20232023-12-31	Liabilities / assets	59.4%	Total Liabilities: 136319000 Open source Total Assets: 229429000 Open source
20242024-12-31	Liabilities / assets	51.1%	Total Liabilities: 152470000 Open source Total Assets: 298420000 Open source
20252025-12-31	Liabilities / assets	41.9%	Total Liabilities: 77449000 Open source Total Assets: 184987000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.88× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	2.17×	Current Assets: 357874000 Open source Current Liabilities: 164643000 Open source
20172017-12-31	Current assets / current liabilities	3.05×	Current Assets: 321995000 Open source Current Liabilities: 105489000 Open source
20182018-12-31	Current assets / current liabilities	4.72×	Current Assets: 173324000 Open source Current Liabilities: 36751000 Open source
20192019-12-31	Current assets / current liabilities	5.17×	Current Assets: 337754000 Open source Current Liabilities: 65341000 Open source
20202020-12-31	Current assets / current liabilities	3.37×	Current Assets: 157719000 Open source Current Liabilities: 46806000 Open source
20212021-12-31	Current assets / current liabilities	4.02×	Current Assets: 88921000 Open source Current Liabilities: 22124000 Open source
20222022-12-31	Current assets / current liabilities	6.08×	Current Assets: 140866000 Open source Current Liabilities: 23172000 Open source
20232023-12-31	Current assets / current liabilities	5.6×	Current Assets: 176547000 Open source Current Liabilities: 31546000 Open source
20242024-12-31	Current assets / current liabilities	5.44×	Current Assets: 246193000 Open source Current Liabilities: 45248000 Open source
20252025-12-31	Current assets / current liabilities	4.88×	Current Assets: 101895000 Open source Current Liabilities: 20867000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 131.45 million Exact value Exact value: -131445000 USD 2016-01-01 – 2016-12-31: -131445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2016-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -131445000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -131445000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/lxrx-20181231.xml#216145 Filing: 000106282219000007 The citation records this snapshot. The page link may show a newer release later.	−USD 175.63 million Exact value Exact value: -175628000 USD 2016-01-01 – 2016-12-31: -175628000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2016-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -175628000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -175628000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/lxrx-20181231.xml#215506 Filing: 000106282219000007 The citation records this snapshot. The page link may show a newer release later.	USD 231,000 Exact value Exact value: 231000 USD 2016-01-01 – 2016-12-31: 231000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2016-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 231000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 231000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/lxrx-20181231.xml#251235 Filing: 000106282219000007 The citation records this snapshot. The page link may show a newer release later.	−USD 175.86 million Calculation and evidence -175628000 − 231000 USD Exact free cash flow: -175859000 USD 2016-01-01 – 2016-12-31: -175628000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 231000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2016-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -175859000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -175628000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/lxrx-20181231.xml#215506 Filing: 000106282219000007 Input fundies:CapitalExpenditure: 231000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/lxrx-20181231.xml#251235 Filing: 000106282219000007 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 122.99 million Exact value Exact value: -122993000 USD 2017-01-01 – 2017-12-31: -122993000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2017-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -122993000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -122993000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282220000015/lxrx-20191231.htm#2351263 Filing: 000106282220000015 The citation records this snapshot. The page link may show a newer release later.	−USD 185.39 million Exact value Exact value: -185394000 USD 2017-01-01 – 2017-12-31: -185394000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2017-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -185394000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -185394000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282220000015/lxrx-20191231.htm#1556673 Filing: 000106282220000015 The citation records this snapshot. The page link may show a newer release later.	USD 228,000 Exact value Exact value: 228000 USD 2017-01-01 – 2017-12-31: 228000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2017-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 228000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 228000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282220000015/lxrx-20191231.htm#1562338 Filing: 000106282220000015 The citation records this snapshot. The page link may show a newer release later.	−USD 185.62 million Calculation and evidence -185394000 − 228000 USD Exact free cash flow: -185622000 USD 2017-01-01 – 2017-12-31: -185394000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 228000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2017-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -185622000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -185394000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282220000015/lxrx-20191231.htm#1556673 Filing: 000106282220000015 Input fundies:CapitalExpenditure: 228000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282220000015/lxrx-20191231.htm#1562338 Filing: 000106282220000015 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 120.55 million Exact value Exact value: -120548000 USD 2018-01-01 – 2018-12-31: -120548000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2018-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -120548000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -120548000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/lxrx-20201231.htm#1755520 Filing: 000106282221000013 The citation records this snapshot. The page link may show a newer release later.	−USD 148.61 million Exact value Exact value: -148607000 USD 2018-01-01 – 2018-12-31: -148607000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2018-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -148607000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -148607000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/lxrx-20201231.htm#1116501 Filing: 000106282221000013 The citation records this snapshot. The page link may show a newer release later.	USD 95,000 Exact value Exact value: 95000 USD 2018-01-01 – 2018-12-31: 95000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2018-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 95000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 95000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/lxrx-20201231.htm#1120776 Filing: 000106282221000013 The citation records this snapshot. The page link may show a newer release later.	−USD 148.7 million Calculation and evidence -148607000 − 95000 USD Exact free cash flow: -148702000 USD 2018-01-01 – 2018-12-31: -148607000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 95000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2018-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -148702000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -148607000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/lxrx-20201231.htm#1116501 Filing: 000106282221000013 Input fundies:CapitalExpenditure: 95000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/lxrx-20201231.htm#1120776 Filing: 000106282221000013 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 130.13 million Exact value Exact value: 130133000 USD 2019-01-01 – 2019-12-31: 130133000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2019-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: 130133000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 130133000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/lxrx-20211231.htm#1669487 Filing: 000106282222000005 The citation records this snapshot. The page link may show a newer release later.	USD 113.81 million Exact value Exact value: 113807000 USD 2019-01-01 – 2019-12-31: 113807000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2019-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: 113807000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 113807000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/lxrx-20211231.htm#1095261 Filing: 000106282222000005 The citation records this snapshot. The page link may show a newer release later.	USD 70,000 Exact value Exact value: 70000 USD 2019-01-01 – 2019-12-31: 70000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2019-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 70000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 70000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/lxrx-20211231.htm#1099410 Filing: 000106282222000005 The citation records this snapshot. The page link may show a newer release later.	USD 113.74 million Calculation and evidence 113807000 − 70000 USD Exact free cash flow: 113737000 USD 2019-01-01 – 2019-12-31: 113807000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 70000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2019-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: 113737000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 113807000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/lxrx-20211231.htm#1095261 Filing: 000106282222000005 Input fundies:CapitalExpenditure: 70000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000005/lxrx-20211231.htm#1099410 Filing: 000106282222000005 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 58.57 million Exact value Exact value: -58574000 USD 2020-01-01 – 2020-12-31: -58574000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2020-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -58574000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58574000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000007/lxrx-20221231.htm#900403 Filing: 000106282223000007 The citation records this snapshot. The page link may show a newer release later.	−USD 142.97 million Exact value Exact value: -142969000 USD 2020-01-01 – 2020-12-31: -142969000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2020-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -142969000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -142969000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000007/lxrx-20221231.htm#1083076 Filing: 000106282223000007 The citation records this snapshot. The page link may show a newer release later.	USD 87,000 Exact value Exact value: 87000 USD 2020-01-01 – 2020-12-31: 87000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2020-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 87000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 87000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000007/lxrx-20221231.htm#1087258 Filing: 000106282223000007 The citation records this snapshot. The page link may show a newer release later.	−USD 143.06 million Calculation and evidence -142969000 − 87000 USD Exact free cash flow: -143056000 USD 2020-01-01 – 2020-12-31: -142969000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 87000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2020-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -143056000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -142969000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000007/lxrx-20221231.htm#1083076 Filing: 000106282223000007 Input fundies:CapitalExpenditure: 87000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000007/lxrx-20221231.htm#1087258 Filing: 000106282223000007 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 87.76 million Exact value Exact value: -87758000 USD 2021-01-01 – 2021-12-31: -87758000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2021-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -87758000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -87758000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm#925016 Filing: 000106282224000008 The citation records this snapshot. The page link may show a newer release later.	−USD 87.02 million Exact value Exact value: -87017000 USD 2021-01-01 – 2021-12-31: -87017000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2021-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -87017000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -87017000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm#950193 Filing: 000106282224000008 The citation records this snapshot. The page link may show a newer release later.	USD 1.22 million Exact value Exact value: 1221000 USD 2021-01-01 – 2021-12-31: 1221000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2021-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 1221000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1221000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm#953153 Filing: 000106282224000008 The citation records this snapshot. The page link may show a newer release later.	−USD 88.24 million Calculation and evidence -87017000 − 1221000 USD Exact free cash flow: -88238000 USD 2021-01-01 – 2021-12-31: -87017000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1221000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2021-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -88238000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87017000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm#950193 Filing: 000106282224000008 Input fundies:CapitalExpenditure: 1221000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm#953153 Filing: 000106282224000008 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 101.94 million Exact value Exact value: -101944000 USD 2022-01-01 – 2022-12-31: -101944000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2022-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -101944000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -101944000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000013/lxrx-20241231.htm#997179 Filing: 000106282225000013 The citation records this snapshot. The page link may show a newer release later.	−USD 88.85 million Exact value Exact value: -88851000 USD 2022-01-01 – 2022-12-31: -88851000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2022-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -88851000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88851000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000013/lxrx-20241231.htm#1024477 Filing: 000106282225000013 The citation records this snapshot. The page link may show a newer release later.	USD 1.33 million Exact value Exact value: 1326000 USD 2022-01-01 – 2022-12-31: 1326000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2022-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 1326000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1326000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000013/lxrx-20241231.htm#1027437 Filing: 000106282225000013 The citation records this snapshot. The page link may show a newer release later.	−USD 90.18 million Calculation and evidence -88851000 − 1326000 USD Exact free cash flow: -90177000 USD 2022-01-01 – 2022-12-31: -88851000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1326000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2022-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -90177000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88851000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000013/lxrx-20241231.htm#1024477 Filing: 000106282225000013 Input fundies:CapitalExpenditure: 1326000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000013/lxrx-20241231.htm#1027437 Filing: 000106282225000013 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 177.12 million Exact value Exact value: -177119000 USD 2023-01-01 – 2023-12-31: -177119000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2023-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -177119000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -177119000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#986241 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 161.9 million Exact value Exact value: -161897000 USD 2023-01-01 – 2023-12-31: -161897000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2023-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -161897000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -161897000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1011738 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	USD 470,000 Exact value Exact value: 470000 USD 2023-01-01 – 2023-12-31: 470000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2023-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 470000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 470000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1014698 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 162.37 million Calculation and evidence -161897000 − 470000 USD Exact free cash flow: -162367000 USD 2023-01-01 – 2023-12-31: -161897000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 470000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2023-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -162367000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -161897000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1011738 Filing: 000106282226000050 Input fundies:CapitalExpenditure: 470000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1014698 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 200.4 million Exact value Exact value: -200403000 USD 2024-01-01 – 2024-12-31: -200403000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2024-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -200403000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -200403000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#985466 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 178.78 million Exact value Exact value: -178780000 USD 2024-01-01 – 2024-12-31: -178780000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2024-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -178780000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -178780000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1011084 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	USD 1.03 million Exact value Exact value: 1031000 USD 2024-01-01 – 2024-12-31: 1031000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2024-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 1031000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1031000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1014107 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 179.81 million Calculation and evidence -178780000 − 1031000 USD Exact free cash flow: -179811000 USD 2024-01-01 – 2024-12-31: -178780000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1031000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2024-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -179811000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -178780000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1011084 Filing: 000106282226000050 Input fundies:CapitalExpenditure: 1031000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1014107 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 50.34 million Exact value Exact value: -50341000 USD 2025-01-01 – 2025-12-31: -50341000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Net Income: -50341000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50341000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#984693 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 67.85 million Exact value Exact value: -67851000 USD 2025-01-01 – 2025-12-31: -67851000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Operating Cash Flow: -67851000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -67851000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1010429 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2025-01-01 – 2025-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1013515 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.	−USD 67.85 million Calculation and evidence -67851000 − 0 USD Exact free cash flow: -67851000 USD 2025-01-01 – 2025-12-31: -67851000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexicon Pharmaceuticals, Inc. · 2025-12-31 Lexicon Pharmaceuticals, Inc. (edgar:1062822) Free cash flow: -67851000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:20:14Z Snapshot: 9493946a16b4a8625aa6804037ad2a67a7f6bf39d1708ef403f90e6aebc3e2cf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1062822?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -67851000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1010429 Filing: 000106282226000050 Input fundies:CapitalExpenditure: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm#1013515 Filing: 000106282226000050 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

190 filings · 5,320 latest values · 5,256 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001062822, 1062822, LXRX, edgar:1062822

Also known as LEXICON GENETICS INC/TX, LEXICON PHARMACEUTICALS, INC., LEXICON PHARMACEUTICALS, INC./DE, Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation